Barclays PLC Bio Xcel Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 88 shares of BTAI stock, worth $30. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 88 -0.0%

Holding current value

$30

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$0.53 - $1.34 $25 - $65	-49 Reduced 35.77%	88 $0
Q2 2024 Aug 14, 2024	SELL	$1.14 - $2.97 $16,683 - $43,465	-14,635 Reduced 99.07%	137 $0
Q1 2024 May 15, 2024	SELL	$1.95 - $4.04 $25,589 - $53,016	-13,123 Reduced 47.04%	14,772 $41,000
Q4 2023 Feb 15, 2024	BUY	$2.32 - $5.51 $46,954 - $111,516	20,239 Added 264.35%	27,895 $82,000
Q3 2023 Nov 07, 2023	SELL	$2.49 - $11.85 $231,729 - $1.1 Million	-93,064 Reduced 92.4%	7,656 $18,000
Q2 2023 Aug 03, 2023	BUY	$6.39 - $28.58 $285,613 - $1.28 Million	44,697 Added 79.78%	100,720 $671,000
Q1 2023 May 04, 2023	BUY	$17.7 - $33.24 $900,699 - $1.69 Million	50,887 Added 990.79%	56,023 $1.05 Million
Q4 2022 Feb 13, 2023	BUY	$10.25 - $22.43 $44,331 - $97,009	4,325 Added 533.29%	5,136 $111,000
Q3 2022 Nov 03, 2022	SELL	$11.19 - $17.89 $18,194 - $29,089	-1,626 Reduced 66.72%	811 $10,000
Q2 2022 Aug 12, 2022	SELL	$9.03 - $21.55 $4,081 - $9,740	-452 Reduced 15.65%	2,437 $32,000
Q1 2022 May 16, 2022	SELL	$15.0 - $22.83 $270,600 - $411,853	-18,040 Reduced 86.2%	2,889 $61,000
Q4 2021 Feb 14, 2022	BUY	$20.12 - $35.09 $213,030 - $371,532	10,588 Added 102.39%	20,929 $426,000
Q3 2021 Nov 09, 2021	BUY	$23.84 - $32.03 $105,587 - $141,860	4,429 Added 74.92%	10,341 $314,000
Q2 2021 Aug 13, 2021	BUY	$29.06 - $38.83 $171,802 - $229,562	5,912 New	5,912 $172,000
Q1 2021 May 13, 2021	SELL	$39.04 - $64.6 $18,739 - $31,007	-480 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$42.46 - $56.58 $1.19 Million - $1.58 Million	-28,007 Reduced 98.32%	480 $22,000
Q3 2020 Nov 12, 2020	BUY	$37.44 - $64.63 $1.04 Million - $1.8 Million	27,887 Added 4647.83%	28,487 $1.24 Million
Q2 2020 Aug 12, 2020	BUY	$17.62 - $58.71 $10,572 - $35,226	600 New	600 $32,000
Q1 2020 May 13, 2020	SELL	$12.26 - $41.14 $85,084 - $285,511	-6,940 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$4.05 - $14.61 $16,070 - $57,972	3,968 Added 133.51%	6,940 $101,000
Q3 2019 Nov 14, 2019	SELL	$7.04 - $11.77 $6,434 - $10,757	-914 Reduced 23.52%	2,972 $21,000
Q2 2019 Aug 14, 2019	BUY	$8.99 - $11.79 $34,935 - $45,815	3,886 New	3,886 $43,000
Q2 2018 Aug 14, 2018	SELL	$7.02 - $11.26 $4.34 Million - $6.96 Million	-618,249 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$9.83 - $11.03 $6.08 Million - $6.82 Million	618,249 New	618,249 $6.33 Million

Others Institutions Holding BTAI

# of Institutions

Shares Held

3.14M

Call Options Held

22.2K

Put Options Held

40.2K

View Full List

About BioXcel Therapeutics, Inc.

Ticker BTAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,022,500
Market Cap $9.81M
Description
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...

More about BTAI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account